Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19

NCT05059106 is registered in ClinicalTrials.gov with Federal University of Espirito Santo as lead sponsor.

NCT NCT05059106
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05059106 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19
Lead sponsor
Federal University of Espirito Santo
Phase
Phase 2/3
Overall status
Unknown status
Start date
June 1, 2021
Completion date
October 30, 2022
Enrollment
29,637 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2